Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Metrics to compare | LONN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLONNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 37.5x | 30.2x | −0.5x | |
PEG Ratio | −0.26 | 0.61 | 0.00 | |
Price/Book | 4.3x | 4.2x | 2.6x | |
Price / LTM Sales | 5.2x | 4.2x | 3.2x | |
Upside (Analyst Target) | 37.1% | 23.1% | 47.4% | |
Fair Value Upside | Unlock | 9.7% | 6.9% | Unlock |